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EDITORIAL
B-TYPE NATRIURETIC PEPTIDE LEVELS – A NEW 
BIOMARKER IN THE ACUTE CORONARY SYNDROME
Katerina Vitlianova
Medical Faculty, University of Sofia “St. Kliment Ohridski” 
Currently, B-type natriuretic peptide (BNP) and N-terminal B-type natriuretic peptide (NT-pro BNP) 
are recommended as diagnostic and risk stratification tools in relation to heart failure (1).  The main stimu-
lus for their secretion is myocardial wall stress in response to myocyte stretch. It is assumed that the elevated 
BNP levels indicate the degree of the ischemia - induced left ventricular dysfunction in relation to the patho-
logical left ventricle strain and overload in patients with ACSs (2). However, the relationship between ischemia 
and LV strain is not ruled out as related to myocardial necrosis as measured by the elevated levels of troponins. 
It has been suggested that the stunned myocardium, ischemic induced diastolic dysfunction, reversible border 
zone injury, apoptosis, acute papillary muscle dysfunction and arrhythmia may precipitate the development of 
acute heart failure in both STEMI and non-STEMI patients (3,4). These pathological changes related to acute 
ischemia, even without substantial loss of myocardial tissue pointed out a significant threat to coronary pa-
tients who developed acute heart failure. BNP has also emerged as a prognostic tool early, within three days, 
after acute coronary syndromes (ACS) (5,6). Patients with higher plasma BNP concentrations measured with-
in the first week after a first myocardial infarction experience adverse left ventricular remodeling, as assessed 
by echocardiography (7). Donald S. C. et al, provide information that bedside BNP levels predict CV events 
at 10 months, independently of echocardiographic abnormalities. The study suggests that BNP enhances risk 
stratification post ACS (8). BNP was also a good predictor of one year cardiac mortality after myocardial in-
farction. Bazzino et al., demonstrated the prognostic value of elevated levels of NT-pro-BNP in ACSs, in addi-
tion to conventional risk classification and markers of myocardial necrosis. This is in accordance with recently 
published results confirming the poor prognosis of patients with ACS and signs of heart failure including pa-
tients without elevated markers of necrosis (9). 
The novel result of the study presented by Kashlov et al. relates the observed significantly increased lev-
els of RIPK3 (Receptor-interacting serine/threonine-protein kinase 3 – a novel regulator of programmed cell 
death in healthy people and generation of reactive oxygen species), 24 hours after the onset of symptoms and 
its strong correlation with NT pro-BNP (10). Although troponins do not correspond with the relationship be-
tween ischemia and LV strain it seems that the levels of RIPK3 correlate with degree of myocardial necrosis in 
STEMI patients with heart failure. Longitudinal studies on that relationships in selected population of patient 
with ACS and heart failure are preferable and needed.
CLINICAL IMPLICATION: 
The challenge addressed in the current report is to identify the patients at highest risk and to define the 
appropriate treatment strategy in patients with ACS who develop acute heart failure concerning the improve-
ment in survival (11,12). The reported findings are valuable in terms of them being in accordance with recent 
reports suggesting that natriuretic peptide has a potential to be a new prognostic biomarker in patients with 
STEMI and its measurement might be integrated into the routine evaluation of patients with ACS (13,14). 
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